Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging
Bioidentical Hormones - U.S. Senate Special Committee on Aging
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
210<br />
,lmcCII na: CLI I tr: tarty versus Late lnterventi<strong>on</strong> Trial With Estradiol<br />
Eligibility<br />
randomized treatment so that <strong>on</strong>ly women exposed to active treatment will receive active progester<strong>on</strong>e.<br />
Participants will receive ultras<strong>on</strong>ography at baseline and every 6 m<strong>on</strong>ths throughout the 2 to 5 years<br />
(average 3 years) of randomized treatment.<br />
Genders Eligible for Study: Female<br />
Accepts Healthy Volunteers<br />
Criteria<br />
Inclusi<strong>on</strong> Criteria:<br />
* Women with a serum estradiol level 25 pg/ml or less<br />
* No period for 6 m<strong>on</strong>ths or more<br />
* Postmenopausal less than 6 years, OR IO years or l<strong>on</strong>ger<br />
Exclusi<strong>on</strong> Criteria:<br />
* Clinical signs, symptoms, or pers<strong>on</strong>al history of cardiovascular disease<br />
* Women who have had a hysterectomy <strong>on</strong>ly and no oophorectomy (since time from menopause<br />
cannot be determined)<br />
* Diabetes mellitus or fasting serum glucose 140 mg/dL or greater<br />
* Unc<strong>on</strong>trolled hypertensi<strong>on</strong> (diastolic blood pressure 110 mmHg or greater)<br />
* Thyroid disease (untreated)<br />
* Serum creatinine greater than 2.0 mg/dL<br />
* Plasma triglyceride levels greater than 500 mg/dL<br />
* Life threatening disease with prognosis less than 5 years<br />
* Cirrhosis or liver disease<br />
* History of deep vein thrombosis or pulm<strong>on</strong>ary embolism<br />
* History of breast cancer<br />
* Current horm<strong>on</strong>e replacement therapy (HRT)<br />
Locati<strong>on</strong> and C<strong>on</strong>tact Informati<strong>on</strong><br />
Please refer to this study by ClinicalTrials.gov identifier NCTOOI 14517<br />
United States, California<br />
Atherosclerosis Research Unit, Divisi<strong>on</strong> of Cardiovascular Medicine, Department of Medicine. Los Angeles,<br />
Califomia, 90033, United States; Recruiting<br />
Howard N. Hodis, MD 866-240-1489 arulusedu<br />
Study chairs or principal investigators<br />
Howard N. Hodis, MD, Principal Investigator, University of Southern Califomia, Atherosclerosis<br />
Research Unit, Divisi<strong>on</strong> of Cardiovascular Medicine, Department of Medicine<br />
More Informati<strong>on</strong><br />
htf -- e liir, ttic I.Av -/,k/.hn,.,.,InwlTAl 1 IA I d In~nrrA<br />
tf7-l1A7